Liver CirrhosisNCT06147947
Liver and Spleen Stiffness Measured by TE and 2D-SWE for Diagnosis of CSPH in Patients With cACLD
An observational study of Liver Cirrhosis and Liver Fibrosis, run by Fifth Affiliated Hospital, Sun Yat-Sen University at 1 site in China.
Trial summary
A observational diagnostic study will be conducted to compare the performance of liver stiffness and spleen stiffness measured by 2D-shear wave elastography (2D-SWE) and transient elastography (TE) for diagnosing clinically significant portal hypertension (CSPH) in people with compensated Advanced Chronic Liver… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Liver Cirrhosis, Liver Fibrosis, Portal Hypertension
- What is being tested?
- Diagnostic Test: Transient elastography (TE) and 2D-shear wave elastography (2D-SWE)
- How many people
- 150 participants
- Where
- 1 siteChina
- Study dates
- 1 Dec 2023to 1 Jan 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with chronic liver disease who visit Fifth Affiliated Hospital, Sun Yat-Sen University will be enrolled from October 2023 to January 2025. Their liver stiffness measured by transient elastography (TE) should be at least 10kPa no previous decompensation symptoms.
Who may be able to join
- Age≥18 years old;
- Chronic liver disease (alcoholic liver disease, chronic hepatitis B, chronic hepatitis C or non-alcoholic fatty liver disease);
- Liver stiffness ≥10kPa measured by transient elastography (TE);
- No previous decompensation-related manifestations (such as ascites, gastrointestinal varicose bleeding, hepatic encephalopathy, etc.);
- Informed consent has been signed.
Who cannot join
- There are contraindications of hepatic venous pressure gradient (HVPG) measurement (such as severe abnormal coagulation function;
- Non-cirrhosis portal hypertension;
- Hepatocellular carcinoma or other advanced malignant tumor;
- Acute liver disease or ALT≥5×ULN;
- A history of splenectomy or splenic embolism;
- Acute or chronic thrombosis of the portal vein;
Show all 12Show fewer
- Pregnancy or HIV infection;
- A history of using non-selective beta blockers (NSBB) or diuretic in the last 3 months;
- Persistent substance abuse other than alcohol;
- A history of transjugular intrahepatic portosystemic shunts (TIPs), endoscopic variceal ligation(EVL) , hardener or tissue gel therapy;
- There are conditions that seriously affect TE and 2D-SWE measurements (such as the intercostal space is too narrow, BMI≥30, etc.);
- Subjects considered unsuitable for including in this study but not included by the above exclusion criteria.
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
The Fifth Affiliated Hospital, Sun Yat-sen University
Zhuhai, Guangdong, 519000
Xi Liu, PhD, +86 15992670630, liuxi26@mail.sysu.edu.cn
About this study
Official title: Liver and Spleen Stiffness Measured by Transient Elastography and 2D-shear Wave Elastography for Diagnosis of the Severity of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease: a Diagnostic Accuracy Study
A observational diagnostic study will be conducted to compare the performance of liver stiffness and spleen stiffness measured by 2D-shear wave elastography (2D-SWE) and transient elastography (TE) for diagnosing clinically significant portal hypertension (CSPH) in people with compensated Advanced Chronic Liver Disease (cACLD), and explore the cut-off value of 2D-SWE for diagnosing clinically significant portal hypertension (CSPH).
Read the detailed description
Patients with chronic liver disease who visit Fifth Affiliated Hospital, Sun Yat-Sen University will be enrolled from October 2023 to January 2025. Their liver stiffness measured by transient elastography (TE) should be at least 10 kilopascal (kPa) and with no previous decompensation symptoms.
Patients will be asked to sign an informed consent form. After that, researchers will assess the eligibility of the participants according to inclusion and exclusion criteria, and record their demographic data, history of disease, and the etiology of liver disease.
The participants will be required to complete relevant laboratory tests such as blood routine, liver function, kidney function, coagulation function and etiology. After completing the tests, the results will be recorded by primary researchers.
Abdominal ultrasound and 2D-shear wave elastography (2D-SWE) will be conducted by a sonographer, the interval between ultrasonic examination and laboratory tests should be less than a week, and the patients should fast for at least 4 hours before the examination. Abdominal ultrasound findings, liver stiffness, spleen stiffness, spleen thickness, spleen diameter, portal vein trunk diameter will be recorded by primary researchers.
TE examination will be conducted by experienced nurses, instructing patients to have a fasting period of at least 4 hours prior to the tests. An interval of no more than 1 week should separate the abdominal ultrasound and 2D-SWE examination. The report will be considered highly reliable only if the interquartile range to median ratio (IQR/med) is ≤ 30%, at least 10 successful acquisitions are obtained, and the success rate is at least 60%. Liver stiffness, spleen stiffness and controlled attenuation parameter (CAP) will be recorded by primary researchers.
Hepatic venous pressure gradient (HVPG) will be conducted by experienced interventionists, There should be a maximum interval of no more than 1 week between the HVPG and ultrasound examination, and patients should fast for at least 2 hours before undergoing HVPG. Primary researchers will record the location of puncture place, the result of wedged hepatic venous pressure (WHVP), the result of free hepatic venous pressure (FHVP) and so on.
Demographic characteristics and laboratory results will be collected to describe participants' condition, and the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under the receiver operating characteristic (AUROC) of 2D-SWE will be compared with that of TE in diagnosing CSPH, and the cut-off value of 2D-SWE for diagnosing CSPH will be explored.
- Conditions
- Liver Cirrhosis, Liver Fibrosis, Portal Hypertension
- Being tested
- Diagnostic Test: Transient elastography (TE) and 2D-shear wave elastography (2D-SWE)
- Keywords
- 2D-SWE, Liver Cirrhosis, Liver Stiffness, Spleen Stiffness, Portal Hypertension
- Medical subject headings
- Liver Cirrhosis, Hypertension, Portal
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Diagnostic Test: Transient elastography (TE) and 2D-shear wave elastography (2D-SWE)Diagnostic test
Index test: TE examination will be completed by experienced nurses, requiring fasting for more than 4 hours before the examination and an interval of no more than 1 week from the abdominal ultrasound and 2D-SWE examination. The report will be considered highly reliable only if IQR/med is ≤ 30%, at least 10 successful acquisitions are obtained, and the success rate is at least 60%. Abdominal ultrasound and 2D-shear wave elastography (2D-SWE) will be completed by a sonographer, the interval between ultrasonic examination and laboratory tests should be less than a week, and the patients should fast for at least 4 hours before the examination.
Reference standard: Hepatic venous pressure gradient (HVPG) will be conducted by experienced interventionists. There should be a maximum interval of no more than 1 week between the HVPG and ultrasound examination, and patients should fast for at least 2 hours before undergoing HVPG.
| Study group | Role | What they receive |
|---|---|---|
| study group | All participants included will be in one study group. Receives: Diagnostic Test: Diagnostic Test: Transient elastography (TE) and 2D-shear wave elastography (2D-SWE) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Sensitivity of TE and 2D-SWE
True Positive/ (True Positive+False Negative) ×100%
Measured: Through study completion, an average of 2 year
Specificity of TE and 2D-SWE
True Negative/ (True Negative+False Positive) ×100%
Measured: Through study completion, an average of 2 year
Positive Predictive Value of TE and 2D-SWE
True Positive/ (True Positive+False Positive) ×100%
Measured: Through study completion, an average of 2 year
Negative Predictive Value of TE and 2D-SWE
True Negative/ (True Negative+False Negative) ×100%
Measured: Through study completion, an average of 2 year
Overall diagnostic performance of TE and 2D-SWE
Measured by the area under the receiver operating characteristic curve (AUROC). The test accuracy level is considered high when the AUROC value is ≥ 0.9.
Measured: Through study completion, an average of 2 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Nov 2023
- Study start1 Dec 2023 (estimated)
- Primary completion1 Jan 2025 (estimated)
- Study completion1 Jan 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Liver CirrhosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Xi Liu, PhD, Principal investigator, Fifth Affiliated Hospital, Sun Yat-Sen University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06147947
- Sponsor's protocol ID
- ZDWY.GRBK.036
- Status last verified
- Nov 2023
- First submitted
- 15 Nov 2023
- Last updated
- 28 Nov 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The datasets generated during and/or analysed during the current study will be available from the principal investigator on reasonable request.
Study at a glance
From the registry record, last updated by the sponsor on 28 Nov 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Liver and Spleen Stiffness Measured by Transient Elastography and 2D-shear Wave Elastography for Diagnosis of the Severity of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease: a Diagnostic Accuracy Study
- ClinicalTrials.gov ID
- NCT06147947
- Acronym / sponsor ID
- ZDWY.GRBK.036
- Conditions
- Liver Cirrhosis, Liver Fibrosis, Portal Hypertension
- Keywords
- 2D-SWE, Liver Cirrhosis, Liver Stiffness, Spleen Stiffness, Portal Hypertension
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen UniversityUniversity, hospital or other
- Study start
- 1 Dec 2023 (estimated)
- Primary completion
- 1 Jan 2025 (estimated)
- Study completion
- 1 Jan 2025 (estimated)
- First posted
- 28 Nov 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A observational diagnostic study will be conducted to compare the performance of liver stiffness and spleen stiffness measured by 2D-shear wave elastography (2D-SWE) and transient elastography (TE) for diagnosing clinically significant portal hypertension (CSPH) in people with compensated Advanced Chronic Liver Disease (cACLD), and explore the cut-off value of 2D-SWE for diagnosing clinically significant portal hypertension (CSPH).
Detailed description
Patients with chronic liver disease who visit Fifth Affiliated Hospital, Sun Yat-Sen University will be enrolled from October 2023 to January 2025. Their liver stiffness measured by transient elastography (TE) should be at least 10 kilopascal (kPa) and with no previous decompensation symptoms.
Patients will be asked to sign an informed consent form. After that, researchers will assess the eligibility of the participants according to inclusion and exclusion criteria, and record their demographic data, history of disease, and the etiology of liver disease.
The participants will be required to complete relevant laboratory tests such as blood routine, liver function, kidney function, coagulation function and etiology. After completing the tests, the results will be recorded by primary researchers.
Abdominal ultrasound and 2D-shear wave elastography (2D-SWE) will be conducted by a sonographer, the interval between ultrasonic examination and laboratory tests should be less than a week, and the patients should fast for at least 4 hours before the examination. Abdominal ultrasound findings, liver stiffness, spleen stiffness, spleen thickness, spleen diameter, portal vein trunk diameter will be recorded by primary researchers.
TE examination will be conducted by experienced nurses, instructing patients to have a fasting period of at least 4 hours prior to the tests. An interval of no more than 1 week should separate the abdominal ultrasound and 2D-SWE examination. The report will be considered highly reliable only if the interquartile range to median ratio (IQR/med) is ≤ 30%, at least 10 successful acquisitions are obtained, and the success rate is at least 60%. Liver stiffness, spleen stiffness and controlled attenuation parameter (CAP) will be recorded by primary researchers.
Hepatic venous pressure gradient (HVPG) will be conducted by experienced interventionists, There should be a maximum interval of no more than 1 week between the HVPG and ultrasound examination, and patients should fast for at least 2 hours before undergoing HVPG. Primary researchers will record the location of puncture place, the result of wedged hepatic venous pressure (WHVP), the result of free hepatic venous pressure (FHVP) and so on.
Demographic characteristics and laboratory results will be collected to describe participants' condition, and the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under the receiver operating characteristic (AUROC) of 2D-SWE will be compared with that of TE in diagnosing CSPH, and the cut-off value of 2D-SWE for diagnosing CSPH will be explored.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| study group | – | Diagnostic Test: Diagnostic Test: Transient elastography (TE) and 2D-shear wave elastography (2D-SWE)All participants included will be in one study group. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with chronic liver disease who visit Fifth Affiliated Hospital, Sun Yat-Sen University will be enrolled from October 2023 to January 2025. Their liver stiffness measured by transient elastography (TE) should be at least 10kPa no previous decompensation symptoms.
Key inclusion criteria (5 listed)
- Age≥18 years old;
- Chronic liver disease (alcoholic liver disease, chronic hepatitis B, chronic hepatitis C or non-alcoholic fatty liver disease);
- Liver stiffness ≥10kPa measured by transient elastography (TE);
- No previous decompensation-related manifestations (such as ascites, gastrointestinal varicose bleeding, hepatic encephalopathy, etc.);
- Informed consent has been signed.
Key exclusion criteria (12 listed)
- There are contraindications of hepatic venous pressure gradient (HVPG) measurement (such as severe abnormal coagulation function;
- Non-cirrhosis portal hypertension;
- Hepatocellular carcinoma or other advanced malignant tumor;
- Acute liver disease or ALT≥5×ULN;
- A history of splenectomy or splenic embolism;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Diagnostic Test: Transient elastography (TE) and 2D-shear wave elastography (2D-SWE)Index test: TE examination will be completed by experienced nurses, requiring fasting for more than 4 hours before the examination and an interval of no more than 1 week from the abdominal ultrasound and 2D-SWE examination. The report will be considered highly reliable only if IQR/med is ≤ 30%, at least 10 successful acquisitions are obtained, and the success rate is at least 60%. Abdominal ultrasound and 2D-shear wave elastography (2D-SWE) will be completed by a sonographer, the interval between ultrasonic examination and laboratory tests should be less than a week, and the patients should fast for at least 4 hours before the examination. Reference standard: Hepatic venous pressure gradient (HVPG) will be conducted by experienced interventionists. There should be a maximum interval of no more than 1 week between the HVPG and ultrasound examination, and patients should fast for at least 2 hours before undergoing HVPG. | Diagnostic test | study group |
Primary outcome
Sensitivity of TE and 2D-SWE
Time frame: Through study completion, an average of 2 year
True Positive/ (True Positive+False Negative) ×100%
Specificity of TE and 2D-SWE
Time frame: Through study completion, an average of 2 year
True Negative/ (True Negative+False Positive) ×100%
Positive Predictive Value of TE and 2D-SWE
Time frame: Through study completion, an average of 2 year
True Positive/ (True Positive+False Positive) ×100%
Negative Predictive Value of TE and 2D-SWE
Time frame: Through study completion, an average of 2 year
True Negative/ (True Negative+False Negative) ×100%
Overall diagnostic performance of TE and 2D-SWE
Time frame: Through study completion, an average of 2 year
Measured by the area under the receiver operating characteristic curve (AUROC). The test accuracy level is considered high when the AUROC value is ≥ 0.9.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Nov 2023.
- Individual participant dataSharing planned: No. The datasets generated during and/or analysed during the current study will be available from the principal investigator on reasonable request.
Related trials for Liver Cirrhosis
RecruitingObservational study
Effectiveness and Clinical Outcomes of Long-term Bulevirtide Monotherapy in Patients With HDV-related Compensated Cirrhosis
Hepatitis D
Recruiting
Optimal Treatment Strategy for Spontaneous Bacterial Peritonitis
Spontaneous Bacterial Peritonitis, Paracentesis
RecruitingObservational study
The Value of Spleen Thickness and Spleen Diameter for Gastroesophageal Varices Diagnosis in Compensated Cirrhosis
Liver Cirrhosis, Gastroesophageal Varices
Recruiting
CirrhosisRx CDS System
Cirrhosis, Decision Support Systems, Clinical
RecruitingPhase 3
Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Xi Liu, PhD principal investigator
Fifth Affiliated Hospital, Sun Yat-Sen University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Liver Cirrhosis and Liver Fibrosis, run by Fifth Affiliated Hospital, Sun Yat-Sen University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 28 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Xi Liu, PhD (+86 15992670630, liuxi26@mail.sysu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Sensitivity of TE and 2D-SWE (time frame: Through study completion, an average of 2 year). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Nov 2023.